Systemic Corticosteroids

Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa

“…As a depot injection, intramuscular delivery may be associated with a prolonged, incremental effect allowing for slow and sustained duration of action as the drug is metabolized. 36 This explains the extended therapeutic action. Based on prior data and clinical experience, we elect to administer a concentration of 40 mg/ml of triamcinolone acetonide using a weight-threshold algorithm (Supplemental Table 2).…”

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

“…This ultimately affects the expression of proteins involved in cell growth and regulation. 3,9 In addition to their anti-inflammatory and anti-proliferative effects, retinoids have demonstrated immunomodulatory and anti-inflammatory benefits by way of stimulating T cell mediated cytotoxic effects, inhibiting the accumulation of leukocytes in the stratum corneum and inhibiting blastogenesis of lymphocytes. 10 Cells infected with human papillomavirus are 10-100 times more sensitive to retinoic acid growth inhibition than uninfected keratinocytes, which may serve as an explanation for the modulation of NMSC development, particularly cSCC.…”

“…Capecitabine is a prodrug of 5′-deoxy-5-fluorouridine, which is ultimately converted to its active metabolite 5-FU by the liver, which subsequently inhibits thymidylate synthase. 31 Capecitabine has been shown to selectively reduce inflammatory cytokines, while simultaneously increasing anti-inflammatory cytokines. It has also been hypothesized that fluorouracil, a metabolite of 5-FU, depletes myeloid-derived suppressor cells, which accumulate during the progression of a malignancy and suppress activation of T cells.…”

“…Treatment may be limited by side effects including palmoplantar erythrodysesthesia, which may occur in up to 71% of patients, as well as acral erythema, stomatitis, pyogenic granulomas, hyperpigmentation and hand-foot syndrome. 31,38 In the case series by Endrizzi et al, 7 of 10 study participants required dose adjustments, and 2 discontinued treatment as a result of adverse effects (AEs). Use may be limited by renal insufficiency as well as the rare presence of dihydropyrimidine dehydrogenase deficiency, which may cause severe toxicity and death.…”

“…Use may be limited by renal insufficiency as well as the rare presence of dihydropyrimidine dehydrogenase deficiency, which may cause severe toxicity and death. 31,39 Currently, there are no guidelines or recommendations for the use of capecitabine as chemoprophylaxis or treatment of NMSC. The NCCN guidelines for the management of cSCC do suggest that capecitabine may be considered in SOTRs when surgery is impractical due to high tumor burden.…”